Severe everolimus-induced steatohepatis: a case report.

Abstract

The mammalian target of rapamycin inhibitors are normally favored as immunosuppressant agents for solid organ transplantation such as kidney, liver or heart. Only in recent years have they been increasingly administered for the treatment of neuroendocrine tumors. Even though mammalian target of rapamycin inhibitors are known to exhibit specific side effects, everolimus-related severe hepatic steatosis has not as yet been described in the literature. We report the case of a 76-year-old man who developed severe hepatic steatosis within four weeks of treatment with everolimus as concomitant tumor therapy for a progressively growing neuroendocrine carcinoma of the ileum. A diagnosis of hepatic steatosis was established using computer tomography and fibroscan©. Other underlying causes for steatosis hepatis could be excluded. Further studies are warranted to explain the underlying mechanisms.

• Authors: Gisela Schieren, Edwin Bölke, Axel Scherer, Andreas Raffel, Peter Arne Gerber, Patric Kröpil, Matthias Schott, Jackson Hamilton, Anne Hayman, Wolfram Trudo Knoefel, Wilfried Budach, Christiane Matuschek
• Journal: European journal of medical research (Eur J Med Res) Vol. 18 Pg. 22 (Jul 03 2013) ISSN: 2047-783X [Electronic] England
• PMID: 23822543 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunosuppressive Agents
• Everolimus
• TOR Serine-Threonine Kinases
• Sirolimus

Topics

• Aged
• Everolimus
• Fatty Liver (chemically induced, diagnosis)
• Humans
• Immunosuppressive Agents (adverse effects)
• Liver Neoplasms (diagnosis)
• Male
• Neuroendocrine Tumors (diagnosis)
• Sirolimus (adverse effects, analogs & derivatives, antagonists & inhibitors)
• TOR Serine-Threonine Kinases (metabolism)
• Treatment Outcome